AVRO - AVROBIO, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.1800
+0.0300 (+2.61%)
At close: 04:00PM EDT
1.1500 -0.03 (-2.54%)
After hours: 07:58PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Gap Up

Gap Up

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1.1500
Open1.1500
Bid1.1500 x 2900
Ask1.1700 x 800
Day's Range1.1400 - 1.1800
52 Week Range0.5600 - 1.9300
Volume513,896
Avg. Volume2,124,903
Market Cap52.044M
Beta (5Y Monthly)1.58
PE Ratio (TTM)N/A
EPS (TTM)-2.1600
Earnings DateAug 07, 2023 - Aug 11, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.58
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AVRO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Business Wire

    AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million

    CAMBRIDGE, Mass., May 22, 2023--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced an agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis for $87.5 million in cash. AVROBIO retains full rights to its portfolio of first-in-class HSC gene therapies for Gaucher disease type 1 and type 3, Hunter syndrome and Pompe disease

  • Benzinga

    Avrobio Touts Positive Data Gene Therapy Trial For Cystinosis, Showing Treatment Durability Of Up To 36 Months

    Avrobio Inc (NASDAQ: AVRO) announced follow-up data demonstrating a durable treatment effect across key measures out to 36 months from a Phase 1/2 trial of an investigational gene therapy for cystinosis, dubbed AVR-RD-04. Cystinosis is characterized by the accumulation of the amino acid cystine (a building block of proteins) within cells due to deficient protein cystinosin. Excess cystine damages cells and often forms crystals that can build up and cause problems in many organs and tissues. The

  • Business Wire

    AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting

    CAMBRIDGE, Mass., May 18, 2023--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced follow-up data demonstrating a durable treatment effect across key measures out to 36 months from a collaborator-sponsored Phase 1/2 clinical trial1 evaluating an investigational gene therapy for the treatment of cystinosis. These data are being presented at the 26th Annual Meeting of the American Society of Gene an

  • Business Wire

    AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update

    CAMBRIDGE, Mass., May 11, 2023--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the first quarter ended March 31, 2023, and provided a business update.

  • Business Wire

    AVROBIO Announces Leadership Transition

    CAMBRIDGE, Mass., May 01, 2023--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced the appointment of Erik Ostrowski as interim Chief Executive Officer effective as of today. Mr. Ostrowski, who will continue as AVROBIO’s Chief Financial Officer, succeeds founding President and CEO Geoff MacKay, who is leaving to join an emerging early-stage company. The Board of Directors has begun a search to ide

  • Business Wire

    AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

    CAMBRIDGE, Mass., March 23, 2023--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year ended Dec. 31, 2022 and provided a business update.

  • Business Wire

    AVROBIO to Participate in Cowen’s 43rd Annual Health Care Conference

    CAMBRIDGE, Mass., March 03, 2023--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in a panel titled "Orphan Neuro Corporate Panel" at Cowen’s 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 10:30 AM ET at the Boston Marriott Copley Place in Boston.

  • Business Wire

    AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023

    CAMBRIDGE, Mass., February 09, 2023--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that updated data suggesting complete biochemical correction in the first pediatric Gaucher disease type 3 (GD3) patient treated with hematopoietic stem cell (HSC) gene therapy, including improvements in major refractory elements of disease, will be presented at the 19th Annual WORLDSymposium™ in Orlando, Flori

  • Business Wire

    AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., January 05, 2023--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 7,500 restricted stock units (RSUs) to one new employee as an inducement award under the company’s 2019 Inducement Plan. The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4).

  • Business Wire

    AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy

    CAMBRIDGE, Mass., December 07, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced new interim pharmacokinetic, pharmacodynamic and clinical efficacy data, showing stabilization or reversal of multiple clinically relevant measures in five patients with Gaucher disease after they received a single dose of AVR-RD-02, an investigational hematopoietic stem cell (HSC) gene therapy. In addition, fo

  • Business Wire

    AVROBIO to Share Comprehensive Gaucher Disease Program Update

    CAMBRIDGE, Mass., November 17, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will host a virtual Gaucher Disease Program Update for analysts and investors on Wednesday, Dec. 7, 2022, starting at 8 am ET.

  • Business Wire

    AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update

    CAMBRIDGE, Mass., November 08, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the third quarter ended Sept. 30, 2022 and provided a business update.

  • Business Wire

    AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit

    CAMBRIDGE, Mass., November 07, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced senior management will be participating in a virtual panel titled "Genomic Medicines – Evolving Regulatory Environment and Path to Approval" at the Sixth Annual Barclays Gene Editing/Therapy Summit on Monday, Nov. 14, 2022 at 12:30 PM ET.

  • Business Wire

    AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., November 03, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 13,000 restricted stock units (RSUs) to two new employees as inducement awards under the company’s 2019 Inducement Plan. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

  • Business Wire

    AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease

    CAMBRIDGE, Mass., October 27, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to AVR-RD-02, a first-in-class investigational gene therapy that genetically modifies patients’ own hematopoietic stem cells (HSCs) to treat Gaucher disease, a rare lysosomal disorder that can lead to multiorgan patho

  • Business Wire

    AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis

    CAMBRIDGE, Mass., October 25, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the sixth and final patient has been dosed in the collaborator-sponsored, Phase 1/2 clinical trial of an investigational gene therapy for the treatment of cystinosis. Cystinosis is a life-threatening disease that causes progressive multi-organ damage, including early, acute kidney disease progressing to end

  • Business Wire

    AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease

    CAMBRIDGE, Mass., October 18, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) to investigational AVR-RD-02, a first-in-class gene therapy that uses patients’ own hematopoietic stem cells to treat Gaucher disease, a rare lysoso

  • Business Wire

    AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

    CAMBRIDGE, Mass., October 11, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported favorable data on the combined use of two state-of-the-art assays to evaluate the genotoxicity risk of integrating vectors used in hematopoietic stem cell (HSC) gene therapy prior to clinical use, at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Oct. 11-14, 2022 in Edinburgh, Sc

  • Business Wire

    AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress

    CAMBRIDGE, Mass., September 27, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will present new preclinical data on novel assays used to evaluate lentiviral vector safety at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Oct. 11-14, 2022 in Edinburgh, Scotland.

  • Business Wire

    AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis

    CAMBRIDGE, Mass., September 20, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to AVR-RD-04, an investigational gene therapy for the treatment of cystinosis, a life-threatening disease that causes progressive multi-organ damage, including early, acute kidney disease progressing to end-stage ki

  • Business Wire

    AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial

    CAMBRIDGE, Mass., September 14, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA), Research Ethics Committee (REC) and Health Research Authority (HRA) have approved the clinical trial application (CTA) submitted by AVROBIO’s collaborators at the University of Manchester, U.K. (UoM) for initiation of the Phase 1/2 clini

  • Business Wire

    AVROBIO to Participate in Four Upcoming Investor Conferences in September

    CAMBRIDGE, Mass., August 31, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in four upcoming investor conferences:

  • Business Wire

    AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update

    CAMBRIDGE, Mass., August 09, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the second quarter ended June 30, 2022 and provided a business update.

  • Business Wire

    AVROBIO to Participate in Two Upcoming Investor Conferences in August

    CAMBRIDGE, Mass., August 01, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences:

  • Business Wire

    AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome

    CAMBRIDGE, Mass., July 13, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for AVR-RD-05, its gene therapy for the treatment of mucopolysaccharidosis type II (MPSII), or Hunter syndrome, a rare and seriously debilitating lysosomal disorder that primarily affects young boys.